Feature | August 28, 2014

University of Michigan First in Nation to Implant Device for Tricuspid Valve Replacement

Heart team implants Edwards Sapien valve for landmark transcatheter tricuspid valve replacement

The Edwards Lifesciences Sapien valve used for transcatheter tricuspid valve replacement at the University of Michigan.

Steven F. Bolling, M.D., cardiac surgeon at the University of Michigan Frankel Cardiovascular Center, lead a mutidisciplinary team in successful transcatheter tricuspid valve replacement.

August 28, 2014 — The University of Michigan Frankel Cardiovascular Center is the first heart center in the nation to perform percutaneous implantation of the Edwards Sapien valve to replace a patient’s tricuspid valve. Cardiac surgeon Steven Bolling, M.D., interventional cardiologist Stanley Chetcuti, M.D., interventional cardiologist Daniel Menees, M.D., and cardiac surgeon Matthew Romano, M.D., successfully completed the procedure Aug. 11.

Because of the less invasive approach, the 47-year-old patient was discharged after only a two-day hospital stay. “Minimally invasive surgery for tricuspid valve replacement is a new solution for the dilemma of treating valve disease in which repeat surgeries are often needed but problematic,” said Bolling, director of the U-M Mitral Valve Clinic. “This was a rewarding result for all of us.”

Compared to the rapid expansion of transcatheter aortic valve replacement (TAVR) procedures, transcatheter tricuspid valve-in-valve implantation is just beginning.

The U-M cardiac team replaced the patient’s diseased heart valve to improve blood flow on the right side of the heart. Tricuspid valve stenosis had caused the valve to narrow. Adding to the complexity, her heart valve had been replaced before using animal tissue.

For more information: www.umcvc.org

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init